Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intravenous Recombinant Human Prourokinase for Acute Medium Vessel Occlusion 4.5-24 Hours After Ischemic Stroke - A Multicenter, Prospective, Randomized, Open-label, Blinded Endpoint Trial（HOPE-MeVO）

NCT07776873 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Anhui Medical University as lead sponsor.

NCT NCT07776873
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07776873 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intravenous Recombinant Human Prourokinase for Acute Medium Vessel Occlusion 4.5-24 Hours After Ischemic Stroke - A Multicenter, Prospective, Randomized, Open-label, Blinded Endpoint Trial（HOPE-MeVO）
Lead sponsor
The First Affiliated Hospital of Anhui Medical University
Phase
Phase 3
Overall status
Recruiting
Start date
October 6, 2026
Completion date
June 30, 2029
Enrollment
616 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke